A new study validates the Sybil AI model for predicting lung cancer risk using low-dose CT in a predominantly Black cohort at an urban safety-net hospital.
Key Details
- 1Study presented at the 2025 IASLC World Conference on Lung Cancer.
- 2Validation conducted at UI Health on 2,092 baseline low-dose CT scans from 2014-2024.
- 3Cohort primarily Non-Hispanic Black (62%), with 13% Hispanic and 4% Asian.
- 4Sybil demonstrated strong Area Under the Curve (AUC): 0.94 (1 yr), 0.90 (2 yr), 0.86 (3 yr), 0.85 (4 yr), 0.80 (5 yr), 0.79 (6 yr).
- 5Results remained strong after restricting to Black participants and excluding recent diagnoses.
- 6The Sybil Implementation Consortium will advance to prospective clinical trials for clinical workflow integration.
Why It Matters
Demonstrating reliable AI performance in racially and socioeconomically diverse settings is crucial for equitable lung cancer screening. This validation may facilitate broader adoption and help address longstanding disparities in lung cancer outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI Showcased as Transformative Force at 2025 NFCR Global Summit
The 2025 NFCR Global Summit spotlighted AI's expanding impact from cancer research to patient care, with experts highlighting breakthroughs in imaging, pathology, and multi-modal analytics.
•EurekAlert
AI Accelerates Solid Tumor Drug Development and Personalized Oncology
AI is expediting the timeline and personalization of solid tumor drug development using multi-omics, imaging, and advanced computational models.
•EurekAlert
Imaging Reveals Skull Changes and Immune Impact in Glioblastoma
Advanced imaging uncovers that glioblastoma affects the skull and immune system, not just the brain.